BioNTech (NASDAQ:BNTX) CEO Sells $3,453,252.33 in Stock

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 36,209 shares of the stock in a transaction that occurred on Friday, October 9th. The shares were sold at an average price of $95.37, for a total value of $3,453,252.33. Following the transaction, the chief executive officer owned 36,209 shares in the company, valued at $3,453,252.33. This trade represents a 50.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Thursday, October 8th, Ugur Sahin sold 27,000 shares of BioNTech stock. The stock was sold at an average price of $92.31, for a total transaction of $2,492,370.00.
• On Wednesday, October 7th, Ugur Sahin sold 24,000 shares of BioNTech stock. The shares were sold at an average price of $95.86, for a total transaction of $2,300,640.00.
• On Tuesday, October 6th, Ugur Sahin sold 21,000 shares of BioNTech stock. The shares were sold at an average price of $96.81, for a total value of $2,033,010.00.
• On Monday, October 5th, Ugur Sahin sold 72,000 shares of BioNTech stock. The shares were sold at an average price of $97.23, for a total value of $7,000,560.00.
• On Thursday, October 1st, Ugur Sahin sold 17,000 shares of BioNTech stock. The stock was sold at an average price of $97.46, for a total transaction of $1,656,820.00.
• On Wednesday, September 30th, Ugur Sahin sold 32,000 shares of BioNTech stock. The stock was sold at an average price of $98.12, for a total transaction of $3,139,840.00.
• On Monday, September 28th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $98.47, for a total transaction of $3,347,980.00.
• On Friday, September 25th, Ugur Sahin sold 27,000 shares of BioNTech stock. The shares were sold at an average price of $98.69, for a total transaction of $2,664,630.00.
• On Thursday, September 24th, Ugur Sahin sold 39,000 shares of BioNTech stock. The stock was sold at an average price of $98.99, for a total transaction of $3,860,610.00.
• On Wednesday, September 23rd, Ugur Sahin sold 30,000 shares of BioNTech stock. The stock was sold at an average price of $99.40, for a total transaction of $2,982,000.00.

BioNTech Price Performance

NASDAQ BNTX traded up $4.90 during trading hours on Friday, hitting $96.96. 1,288,649 shares of the company’s stock traded hands, compared to its average volume of 1,088,842. The company has a market capitalization of $24.52 billion, a PE ratio of -12.38 and a beta of 1.25. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.85 and a quick ratio of 7.80. BioNTech SE Sponsored ADR has a 52-week low of $79.52 and a 52-week high of $124.00. The firm’s 50-day moving average is $99.04 and its 200-day moving average is $95.16.

BioNTech (NASDAQ:BNTX) last released its earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). The business had revenue of $122.31 million during the quarter, compared to analysts’ expectations of $180.18 million. BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.The company’s revenue for the quarter was down 59.5% compared to the same quarter last year. During the same period last year, the business earned ($1.60) earnings per share. Equities analysts forecast that BioNTech SE Sponsored ADR will post -6.37 EPS for the current fiscal year.

Hedge Funds Weigh In On BioNTech

A number of hedge funds have recently made changes to their positions in BNTX. Integrated Wealth Concepts LLC acquired a new position in BioNTech during the second quarter worth $39,000. Farther Finance Advisors LLC grew its position in BioNTech by 31.5% in the 3rd quarter. Farther Finance Advisors LLC now owns 493 shares of the company’s stock valued at $48,000 after acquiring an additional 118 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its stake in BioNTech by 1,012.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 556 shares of the company’s stock worth $53,000 after purchasing an additional 506 shares during the period. Vestcor Inc purchased a new stake in BioNTech during the fourth quarter worth about $153,000. Finally, Rockefeller Capital Management L.P. lifted its position in shares of BioNTech by 328.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,856 shares of the company’s stock worth $177,000 after purchasing an additional 1,423 shares in the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on BNTX. UBS Group restated a “buy” rating on shares of BioNTech in a report on Wednesday, September 16th. Citigroup cut their price target on shares of BioNTech from $130.00 to $125.00 and set a “buy” rating for the company in a report on Wednesday, August 5th. Argus began coverage on BioNTech in a research report on Thursday. They issued a “hold” rating for the company. Wall Street Zen cut BioNTech from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Finally, Morgan Stanley reduced their target price on BioNTech from $115.00 to $114.00 and set an “overweight” rating on the stock in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $125.69.

About BioNTech

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company’s research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.

BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world.